Newsroom

July 2018

• Press release Jul 30, 2018

  Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention

  Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and…
• 
  Story Jul 30, 2018 Discovery

  Quest for a new measure of mental health

  Novartis researchers are searching for more effective ways to discover drugs for neurological and psychiatric diseases.

• Press release Jul 27, 2018

  Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

  Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is…
• Press release Jul 27, 2018

  Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma

  Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with…
• Press release Jul 23, 2018

  Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke

  Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million…
• Press release Jul 19, 2018

  Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis

  Novartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to…
• Press release Jul 18, 2018

  Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

  Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer…
• Ad hoc release Jul 18, 2018

  Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

  Net sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD…
• Ad hoc release Jul 18, 2018

  Novartis réalise une solide croissance au deuxième trimestre et poursuit sa transformation en une entreprise axée sur les médicaments

  Hausse du chiffre d'affaires net de 5% (tcc[1], +7% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 701 millions, (+40% tcc), enregistrant une forte croissance dans toutes ses…
• Ad hoc release Jul 18, 2018

  Novartis erzielt im zweiten Quartal ein solides Wachstum und setzt die Transformation zu einem fokussierten Arzneimittelunternehmen fort

  Der Nettoumsatz steigt um 5% (kWk[1], +7% USD), vor allem dank folgender Beiträge: Cosentyx erreicht USD 701 Millionen (+40% kWk) mit starken Zuwächsen bei allen Indikationen in den USA und der…
• Statement Jul 13, 2018

  Essential Consultants – Updates

• 
  Story Jul 02, 2018 Discovery

  Drug development gets big data analytics boost

  With Nerve Live, Novartis is harnessing the power of data for the benefit of patients.